iPSC Derived Cardiac Microchambers for Embryonic Drug Screening

iPSC 衍生的心脏微室用于胚胎药物筛选

• 批准号: 8953685
• 负责人: KEVIN Edward HEALY
• 金额: $ 23.54万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8953685
• 关键词: Address; Adult; Affect; Behavior; Biochemical; Biological Assay; Bipolar Disorder; Cardiac; Cardiac Myocytes; Cardiac development; Categories; Cells; Classification; Clinical Trials; Communities; Congenital Abnormality; Congenital Heart Defects; Cues; Data; Development; Developmental Process; Devices; Disease; Drug Interactions; Drug Prescriptions; Drug toxicity; Drug usage; Embryo; Embryonic Development; Exposure to; Fetal Development; Fetus; Genetic; Geometry; Heart; Heart Diseases; Height; Human; Hypoplastic Left Heart Syndrome; In Vitro; Left ventricular structure; Lithium; Medicine; Modeling; Morphogenesis; Myocardium; Organ; Organogenesis; Pathway interactions; Patients; Pattern; Pharmaceutical Preparations; Phenotype; Physicians; Physiological; Physiology; Population; Positioning Attribute; Preclinical Drug Evaluation; Pregnancy; Pregnant Women; Regulation; Reporting; Risk; Rodent; Role; Safety; Shapes; Structure; System; Testing; Tissue Engineering; Tissues; Toxicology; United States; Ventricular; Woman; Work; base; biophysical properties; cardiogenesis; clinical practice; commercialization; culture plates; developmental toxicity; drug discovery; fetal; improved; in vitro Model; in vivo; induced pluripotent stem cell; post-market research; pregnant; prototype; public health relevance; response; screening; tissue culture

 DESCRIPTION: In this application, we aim to establish an in vitro model to recapitulate early heart development for safety assessment of specific drugs commonly administrated during pregnancy. In aim 1, we will test our hypothesis that cardiac tissue morphogenesis can be modeled in vitro by micro patterning and differentiation of human induced pluripotent stem cells (hiPSCs). We will establish and optimize our in vitro early developing heart model by obtaining a full spectrum of 3D cardiac micro tissues generated from hiPSC patterns with different geometries. In aim 2, we will validate our model by the drugs listed in pregnancy risk categories A and X as negative and positive controls, so we will be able to predict the drug toxicity from categories B-D on early heart development.